Login to Your Account

After years of platform building, Clover sees 'blue sky opportunity'

By Cornelia Zou
Staff Writer

Wednesday, February 7, 2018

HONG KONG – An 11-year-old Chinese biopharma company has recently entered the public's eye with a $10 million series A funding and a clinical trial approval by the CFDA for its biosimilar etanercept.

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription